vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and WESBANCO INC (WSBC). Click either name above to swap in a different company.
WESBANCO INC is the larger business by last-quarter revenue ($257.2M vs $191.2M, roughly 1.3× Axsome Therapeutics, Inc.). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs 31.9%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
WesBanco, Inc., is a bank holding company headquartered in Wheeling, West Virginia, United States. It has over 200 branches in West Virginia, Ohio, Western Pennsylvania, Kentucky, Maryland, and Southern Indiana.
AXSM vs WSBC — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $257.2M |
| Net Profit | — | $88.6M |
| Gross Margin | — | — |
| Operating Margin | -33.1% | — |
| Net Margin | — | 34.5% |
| Revenue YoY | 57.4% | — |
| Net Profit YoY | — | 54.4% |
| EPS (diluted) | — | $0.88 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | $257.2M | ||
| Q4 25 | $196.0M | $265.6M | ||
| Q3 25 | $171.0M | $261.6M | ||
| Q2 25 | $150.0M | $260.7M | ||
| Q1 25 | $121.5M | $193.2M | ||
| Q4 24 | $118.8M | $162.9M | ||
| Q3 24 | $104.8M | $150.8M | ||
| Q2 24 | $87.2M | $147.9M |
| Q1 26 | — | $88.6M | ||
| Q4 25 | $-28.6M | $91.1M | ||
| Q3 25 | $-47.2M | $83.6M | ||
| Q2 25 | $-48.0M | $57.4M | ||
| Q1 25 | $-59.4M | $-9.0M | ||
| Q4 24 | $-74.9M | $49.6M | ||
| Q3 24 | $-64.6M | $37.3M | ||
| Q2 24 | $-79.3M | $28.9M |
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | 43.2% | ||
| Q3 25 | -27.0% | 39.5% | ||
| Q2 25 | -24.5% | 27.2% | ||
| Q1 25 | -46.9% | -5.0% | ||
| Q4 24 | -61.1% | 38.0% | ||
| Q3 24 | -59.8% | 29.7% | ||
| Q2 24 | -89.5% | 23.7% |
| Q1 26 | — | 34.5% | ||
| Q4 25 | -14.6% | 34.3% | ||
| Q3 25 | -27.6% | 31.9% | ||
| Q2 25 | -32.0% | 22.0% | ||
| Q1 25 | -48.9% | -4.7% | ||
| Q4 24 | -63.1% | 30.5% | ||
| Q3 24 | -61.7% | 24.7% | ||
| Q2 24 | -91.0% | 19.5% |
| Q1 26 | — | $0.88 | ||
| Q4 25 | $-0.55 | $0.97 | ||
| Q3 25 | $-0.94 | $0.84 | ||
| Q2 25 | $-0.97 | $0.57 | ||
| Q1 25 | $-1.22 | $-0.15 | ||
| Q4 24 | $-1.54 | $0.72 | ||
| Q3 24 | $-1.34 | $0.54 | ||
| Q2 24 | $-1.67 | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | — |
| Total DebtLower is stronger | $70.0M | — |
| Stockholders' EquityBook value | — | $4.1B |
| Total Assets | $713.6M | $27.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | — | ||
| Q4 25 | $322.9M | $956.1M | ||
| Q3 25 | $325.3M | $1.0B | ||
| Q2 25 | $303.0M | $1.2B | ||
| Q1 25 | $300.9M | $1.1B | ||
| Q4 24 | $315.4M | $568.1M | ||
| Q3 24 | $327.3M | $620.9M | ||
| Q2 24 | $315.7M | $486.8M |
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $4.1B | ||
| Q4 25 | $88.3M | $4.0B | ||
| Q3 25 | $73.7M | $4.1B | ||
| Q2 25 | $73.1M | $3.8B | ||
| Q1 25 | $53.2M | $3.8B | ||
| Q4 24 | $57.0M | $2.8B | ||
| Q3 24 | $92.9M | $2.8B | ||
| Q2 24 | $102.9M | $2.5B |
| Q1 26 | $713.6M | $27.5B | ||
| Q4 25 | $689.8M | $27.7B | ||
| Q3 25 | $669.3M | $27.5B | ||
| Q2 25 | $639.8M | $27.6B | ||
| Q1 25 | $596.7M | $27.4B | ||
| Q4 24 | $568.5M | $18.7B | ||
| Q3 24 | $561.5M | $18.5B | ||
| Q2 24 | $548.2M | $18.1B |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
WSBC
| Net Interest Income | $215.4M | 84% |
| Noninterest Income | $41.8M | 16% |
